Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Oligomeric Enteral Nutrition in Undernutrition, due to Oncology Treatment-Related Diarrhea. Systematic Review and Proposal of An Algorithm of Action.

Sanz-Paris A, Martinez-García M, Martinez-Trufero J, Lambea-Sorrosal J, Calvo-Gracia F, López-Alaminos ME.

Nutrients. 2019 Aug 13;11(8). pii: E1888. doi: 10.3390/nu11081888. Review.

2.

Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial.

Judson I, Morden JP, Kilburn L, Leahy M, Benson C, Bhadri V, Campbell-Hewson Q, Cubedo R, Dangoor A, Fox L, Hennig I, Jarman K, Joubert W, Kernaghan S, López Pousa A, McNeil C, Seddon B, Snowdon C, Tattersall M, Toms C, Martinez Trufero J, Bliss JM.

Lancet Oncol. 2019 Jul;20(7):1023-1034. doi: 10.1016/S1470-2045(19)30215-3. Epub 2019 May 31.

3.

Are Comorbidities Associated With Overall Survival in Patients With Oral Squamous Cell Carcinoma?

Jariod-Ferrer ÚM, Arbones-Mainar JM, Gavin-Clavero MA, Simón-Sanz MV, Moral-Saez I, Cisneros-Gimeno AI, Martinez-Trufero J.

J Oral Maxillofac Surg. 2019 Sep;77(9):1906-1914. doi: 10.1016/j.joms.2019.03.007. Epub 2019 Mar 19.

PMID:
30980811
4.

Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.

Garcia-Carbonero R, Marquez-Rodas I, de la Cruz-Merino L, Martinez-Trufero J, Cabrera MA, Piulats JM, Capdevila J, Grande E, Martin-Algarra S, Berrocal A.

Oncologist. 2019 Oct;24(10):1375-1383. doi: 10.1634/theoncologist.2018-0718. Epub 2019 Apr 8. Review.

PMID:
30962295
5.

Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.

Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.

Lancet Oncol. 2019 Jan;20(1):134-144. doi: 10.1016/S1470-2045(18)30676-4. Epub 2018 Dec 18.

PMID:
30578023
6.

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).

Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A.

Oncologist. 2019 Jun;24(6):e338-e346. doi: 10.1634/theoncologist.2018-0121. Epub 2018 Nov 8.

PMID:
30409793
7.

Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.

Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.

Clin Cancer Res. 2018 Nov 1;24(21):5239-5249. doi: 10.1158/1078-0432.CCR-18-0851. Epub 2018 Jul 23.

8.

Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.

Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J.

Oncotarget. 2018 Apr 3;9(25):17576-17588. doi: 10.18632/oncotarget.24799. eCollection 2018 Apr 3.

9.

Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.

García Del Muro X, Maurel J, Martínez Trufero J, Lavernia J, López Pousa A, de Las Peñas R, Cubedo R, Berros JP, Casado Herráez A, de Juan A, Martín Broto J.

Invest New Drugs. 2018 Jun;36(3):468-475. doi: 10.1007/s10637-018-0583-z. Epub 2018 Mar 12.

PMID:
29527631
10.

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

Martin-Liberal J, López-Pousa A, Martínez-Trufero J, Martín-Broto J, Cubedo R, Lavernia J, Redondo A, López-Martín JA, Mulet-Margalef N, Sanjuan X, Tirado ÒM, Garcia-Del-Muro X.

Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.

PMID:
29177953
11.

SEOM clinical guideline in nasopharynx cancer (2017).

Pastor M, Lopez Pousa A, Del Barco E, Perez Segura P, Astorga BG, Castelo B, Bonfill T, Martinez Trufero J, Grau JJ, Mesia R.

Clin Transl Oncol. 2018 Jan;20(1):84-88. doi: 10.1007/s12094-017-1777-0. Epub 2017 Nov 2.

12.

Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).

Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.

Ann Oncol. 2017 Dec 1;28(12):2994-2999. doi: 10.1093/annonc/mdx536.

PMID:
29045512
13.

Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).

Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Alvarez R, Martinez-Trufero J, Lopez-Martin JA, Correa R, Cruz J, Lopez-Pousa A, Santos A, García Del Muro X, Martin-Broto J.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1113-1131. doi: 10.1007/s00280-017-3436-0. Epub 2017 Oct 16.

14.

GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).

Mora J, Castañeda A, Perez-Jaume S, Lopez-Pousa A, Maradiegue E, Valverde C, Martin-Broto J, Garcia Del Muro X, Cruz O, Cruz J, Martinez-Trufero J, Maurel J, Vaz MA, de Alava E, de Torres C.

Br J Cancer. 2017 Sep 5;117(6):767-774. doi: 10.1038/bjc.2017.252. Epub 2017 Aug 8.

15.

Desmoid-Type Fibromatosis: Who, When, and How to Treat.

Martínez Trufero J, Pajares Bernad I, Torres Ramón I, Hernando Cubero J, Pazo Cid R.

Curr Treat Options Oncol. 2017 May;18(5):29. doi: 10.1007/s11864-017-0474-0. Review.

PMID:
28439797
16.

Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).

Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R.

Oral Oncol. 2017 Jul;70:58-64. doi: 10.1016/j.oraloncology.2017.04.004. Epub 2017 Apr 17. Review.

17.

Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.

Mesía R, Garcia-Saenz JA, Lozano A, Pastor M, Grau JJ, Martínez-Trufero J, Lambeaz J, Martínez-Galán J, Mel JR, González B, Vázquez S, Mañós M, Taberna M, Cirauqui B, Del Barco E, Casado E, Rubió-Casadevall J, Rodríguez-Jaráiz A, Cruz JJ; Spanish Head And Neck Cancer Cooperative Group (Study TTCC-2007/02).

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):473-480. doi: 10.1016/j.ijrobp.2016.11.016. Epub 2016 Nov 17.

PMID:
28011050
18.

SEOM Clinical Guideline of management of soft-tissue sarcoma (2016).

López-Pousa A, Martin Broto J, Martinez Trufero J, Sevilla I, Valverde C, Alvarez R, Carrasco Alvarez JA, Cruz Jurado J, Hindi N, Garcia Del Muro X.

Clin Transl Oncol. 2016 Dec;18(12):1213-1220. doi: 10.1007/s12094-016-1574-1.

19.

Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.

Del Barco Morillo E, Mesía R, Adansa Klain JC, Vázquez Fernández S, Martínez-Galán J, Pastor Borgoñon M, González-Rivas C, Caballero Daroqui J, Berrocal A, Martínez-Trufero J, Vera R, Cruz-Hernández JJ; Spanish Head And Neck Cancer Cooperative Group (TTCC).

Oral Oncol. 2016 Nov;62:54-59. doi: 10.1016/j.oraloncology.2016.09.009. Epub 2016 Oct 8.

PMID:
27865372
20.

Metastatic extraskeletal Ewing's sarcoma treated with trabectedin: A case report.

Hernando-Cubero J, Sanz-Moncasi P, Hernández-García A, Pajares-Bernard I, Martínez-Trufero J.

Oncol Lett. 2016 Oct;12(4):2936-2941. Epub 2016 Aug 3.

21.

Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study.

Maurel J, López-Pousa A, Calabuig S, Bagué S, Del Muro XG, Sanjuan X, Rubió-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, García-Albéniz X, Martín-Broto J, de Alava E.

Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6. eCollection 2016.

22.

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.

Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.

J Clin Oncol. 2016 Jul 1;34(19):2294-302. doi: 10.1200/JCO.2015.65.3329. Epub 2016 May 16.

PMID:
27185843
23.

Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location.

Seijas-Tamayo R, Fernández-Mateos J, Adansa Klain JC, Mesía R, Pastor Borgoñón M, Pérez-Ruiz E, Vázquez Fernández S, Salvador Coloma C, Rueda Domínguez A, Taberna M, Martínez-Trufero J, Bonfill Abella T, Vázquez Estévez S, Pollán M, Del Barco Morillo E, Cruz-Hernández JJ.

Clin Transl Oncol. 2016 Nov;18(11):1114-1122. Epub 2016 Apr 25.

PMID:
27112939
24.

Role of surgery in patients with recurrent, metastatic, or unresectable locally advanced gastrointestinal stromal tumors sensitive to imatinib: a retrospective analysis of the Spanish Group for Research on Sarcoma (GEIS).

Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, Del Muro JG, Fra J, Redondo A, Lainez N, Poveda A, Valverde C, De Juan A, Sevilla I, Casado A, Andres R, Cruz J, Martin-Broto J, Maurel J; Spanish Group for Research on Sarcoma (GEIS).

Ann Surg Oncol. 2015 Sep;22(9):2948-57. doi: 10.1245/s10434-014-4360-8. Epub 2015 Jan 22.

PMID:
25608769
25.

A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.

Hitt R, Grau JJ, López-Pousa A, Berrocal A, García-Girón C, Irigoyen A, Sastre J, Martínez-Trufero J, Brandariz Castelo JA, Verger E, Cruz-Hernández JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC).

Ann Oncol. 2014 Jan;25(1):216-25. doi: 10.1093/annonc/mdt461. Epub 2013 Nov 19.

PMID:
24256848
26.

MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.

Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez-Serra A, Lopez-Pousa A, Gronchi A.

Mol Cancer Ther. 2014 Jan;13(1):249-59. doi: 10.1158/1535-7163.MCT-13-0406. Epub 2013 Oct 21.

27.

Sorafenib in metastatic thyroid cancer.

Capdevila J, Iglesias L, Halperin I, Segura A, Martínez-Trufero J, Vaz MÁ, Corral J, Obiols G, Grande E, Grau JJ, Tabernero J.

Endocr Relat Cancer. 2012 Apr 10;19(2):209-16. doi: 10.1530/ERC-11-0351. Print 2012 Apr.

PMID:
22285864
28.

SEOM clinical guidelines for the treatment of thyroid cancer.

Martínez Trufero J, Capdevilla J, Cruz JJ, Isla D.

Clin Transl Oncol. 2011 Aug;13(8):574-9. doi: 10.1007/s12094-011-0700-3.

PMID:
21821493
29.

Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.

García-Del-Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, Gómez-España A, Fra J, Cruz J, Poveda A, Meana A, Pericay C, Cubedo R, Rubió J, De Juan A, Laínez N, Carrasco JA, de Andrés R, Buesa JM; Spanish Group for Research on Sarcomas.

J Clin Oncol. 2011 Jun 20;29(18):2528-33. doi: 10.1200/JCO.2010.33.6107. Epub 2011 May 23.

PMID:
21606430
30.

Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.

Fuster D, Ayuso JR, Poveda A, Cubedo R, Casado A, Martínez-Trufero J, López-Pousa A, Del Muro XG, Lomeña F, Maurel J, Pons F.

Q J Nucl Med Mol Imaging. 2011 Dec;55(6):680-7. Epub 2010 Dec 9.

PMID:
21150863
31.

Response to trabectedin treatment in a highly pretreated patient with an advanced meningeal hemangiopericytoma.

Martinez-Trufero J, Alfaro J, Felipo F, Alvarez M, Madani J, Cebollero A.

Anticancer Drugs. 2010 Sep;21(8):795-8. doi: 10.1097/CAD.0b013e32833d19f0.

PMID:
20622667
32.

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.

Maurel J, Martins AS, Poveda A, López-Guerrero JA, Cubedo R, Casado A, Martínez-Trufero J, Ramón Ayuso J, Lopez-Pousa A, Garcia-Albeniz X, Garcia del Muro X, de Alava E.

Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111.

33.

Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment.

Martinez-Trufero J, Isla D, Adansa JC, Irigoyen A, Hitt R, Gil-Arnaiz I, Lambea J, Lecumberri MJ, Cruz JJ.

Br J Cancer. 2010 Jun 8;102(12):1687-91. doi: 10.1038/sj.bjc.6605697. Epub 2010 May 18.

34.

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study.

Martin-Broto J, Gutierrez A, Garcia-del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, de Sande LM, Lainez N, Maurel J, De Juan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-España A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A.

Ann Oncol. 2010 Jul;21(7):1552-7. doi: 10.1093/annonc/mdq047. Epub 2010 Mar 15.

PMID:
20231303
35.

Skull metastasis from rectal gastrointestinal stromal tumours.

Gil-Arnaiz I, Martínez-Trufero J, Pazo-Cid RA, Felipo F, Lecumberri MJ, Calderero V.

Clin Transl Oncol. 2009 Sep;11(9):625-7.

PMID:
19776004
36.

Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.

Maurel J, López-Pousa A, de Las Peñas R, Fra J, Martín J, Cruz J, Casado A, Poveda A, Martínez-Trufero J, Balañá C, Gómez MA, Cubedo R, Gallego O, Rubio-Viqueira B, Rubió J, Andrés R, Sevilla I, de la Cruz JJ, Del Muro XG, Buesa JM.

J Clin Oncol. 2009 Apr 10;27(11):1893-8. doi: 10.1200/JCO.2008.19.2930. Epub 2009 Mar 9.

PMID:
19273704
37.

Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.

López-Pousa A, Losa R, Martín J, Maurel J, Fra J, Sierra M, Casado A, García Del Muro J, Poveda A, Balañá C, Martínez-Trufero J, Esteban E, Buesa JM.

Br J Cancer. 2006 Jun 19;94(12):1797-802. Epub 2006 May 23.

38.

Serum markers and prognosis in locally advanced breast cancer.

Martínez-Trufero J, de Lobera AR, Lao J, Puértolas T, Artal-Cortés A, Zorrilla M, Alonso V, Pazo R, Valero MI, Ríos-Mitchell MJ, Calderero V, Herrero A, Antón A.

Tumori. 2005 Nov-Dec;91(6):522-30.

PMID:
16457152
39.

Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H.

J Clin Oncol. 2005 Dec 1;23(34):8636-45. Epub 2005 Nov 7. Erratum in: J Clin Oncol. 2006 Feb 20;24(6):1015.

PMID:
16275937
40.

A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.

Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J; Spanish Group for Research on Sarcomas.

Cancer. 2005 Oct 15;104(8):1706-12.

41.

Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).

Maurel J, Buesa J, López-Pousa A, del Muro XG, Quintana MJ, Martín J, Casado A, Martínez-Trufero J, de Las Peñas R, Balañá C.

J Surg Oncol. 2004 Oct 1;88(1):44-9.

PMID:
15384088
42.

Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).

Maurel J, Fra J, López-Pousa A, García del Muro X, Balañá C, Casado A, Martín J, Martínez-Trufero J, de las Peñas R, Buesa JM; Spanish Group for Research on Sarcomas (GEIS).

Cancer. 2004 Apr 1;100(7):1498-506.

43.

Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.

Artal-Cortés A, Martínez-Trufero J, Herrero A, Puértolas T, Alonso V, Corral M, Ceballos C, Maurel J, Antón A.

Anticancer Drugs. 2003 Feb;14(2):111-8.

PMID:
12569297
44.

Phase I trial of weekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer.

Alonso V, Escudero P, Zorrilla M, Isla MD, Herrero A, Mayordomo JI, Martinez-Trufero J, Sáenz A, Tres A, Antón A.

Eur J Cancer. 2001 Dec;37(18):2385-91.

PMID:
11720832
45.

Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.

Maurel J, Zorrilla M, Puertolas T, Antón A, Herrero A, Artal A, Alonso V, Martinez-Trufero J, Puertas MM.

Anticancer Drugs. 2001 Oct;12(9):713-7.

PMID:
11593051
46.

Prognostic impact of bulky mediastinal lymph nodes (N2>2.5 cm) in patients with locally advanced non-small-cell lung cancer (LA-NSCLC) treated with platinum-based induction chemotherapy.

Maurel J, Martinez-Trufero J, Artal A, Martin C, Puertolas T, Zorrrilla M, Herrero A, Antón A, Rosell R.

Lung Cancer. 2000 Nov;30(2):107-16.

PMID:
11086204
47.

[Parenteral nutrition in oncologic patients].

Amador Rodríguez MP, Artal Cortés A, Rebollar Torres E, Idoipe Tomás A, Palomo Palomo P, Martínez Trufero J.

Nutr Hosp. 1998 Jul-Aug;13(4):198-204. Spanish.

PMID:
9780753

Supplemental Content

Loading ...
Support Center